Burzynski Research Institute, Inc. (BZYR)
USD 0.05
(-1.63%)
USD 0.05
(-1.63%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 27.43 Thousand USD | 75.17% |
| 2023 | 15.66 Thousand USD | 353.29% |
| 2022 | 3455.00 USD | -92.62% |
| 2021 | 46.79 Thousand USD | -72.86% |
| 2020 | 172.44 Thousand USD | -17.42% |
| 2019 | 208.82 Thousand USD | 52.84% |
| 2018 | 136.62 Thousand USD | 212.42% |
| 2017 | 43.73 Thousand USD | -58.35% |
| 2016 | 105 Thousand USD | -26.05% |
| 2015 | 141.99 Thousand USD | -7.14% |
| 2014 | 152.9 Thousand USD | 72.6% |
| 2013 | 88.59 Thousand USD | 42.97% |
| 2012 | 61.96 Thousand USD | -14.94% |
| 2011 | 72.85 Thousand USD | 1.95% |
| 2010 | 71.45 Thousand USD | -31.16% |
| 2009 | 103.8 Thousand USD | 51.41% |
| 2008 | 68.55 Thousand USD | 3.71% |
| 2007 | 66.1 Thousand USD | 33.01% |
| 2006 | 49.69 Thousand USD | -42.64% |
| 2005 | 86.64 Thousand USD | -18.82% |
| 2004 | 106.73 Thousand USD | 51.5% |
| 2003 | 70.45 Thousand USD | 21.81% |
| 2002 | 57.83 Thousand USD | -32.01% |
| 2001 | 85.06 Thousand USD | -59.3% |
| 2000 | 209.02 Thousand USD | -38.42% |
| 1999 | 339.4 Thousand USD | -59.37% |
| 1998 | 835.38 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 27.43 Thousand USD | -23.47% |
| 2024 FY | 27.43 Thousand USD | 75.17% |
| 2024 Q2 | 6273.00 USD | -91.21% |
| 2024 Q1 | 71.36 Thousand USD | 355.69% |
| 2024 Q3 | 35.84 Thousand USD | 471.45% |
| 2023 Q3 | 28.42 Thousand USD | 85.7% |
| 2023 FY | 15.66 Thousand USD | 353.29% |
| 2023 Q4 | 15.66 Thousand USD | -44.89% |
| 2023 Q1 | 44.14 Thousand USD | 1177.74% |
| 2023 Q2 | 15.3 Thousand USD | -65.33% |
| 2022 Q3 | 1389.00 USD | -95.32% |
| 2022 Q4 | 3455.00 USD | 148.74% |
| 2022 Q1 | 63.24 Thousand USD | 35.14% |
| 2022 Q2 | 29.67 Thousand USD | -53.08% |
| 2022 FY | 3455.00 USD | -92.62% |
| 2021 Q2 | 204.34 Thousand USD | -19.73% |
| 2021 FY | 46.79 Thousand USD | -72.86% |
| 2021 Q3 | 131.17 Thousand USD | -35.81% |
| 2021 Q1 | 254.56 Thousand USD | 47.62% |
| 2021 Q4 | 46.79 Thousand USD | -64.32% |
| 2020 Q3 | 215.94 Thousand USD | -5.52% |
| 2020 FY | 172.44 Thousand USD | -17.42% |
| 2020 Q1 | 212.88 Thousand USD | 1.95% |
| 2020 Q2 | 228.55 Thousand USD | 7.36% |
| 2020 Q4 | 172.44 Thousand USD | -20.14% |
| 2019 Q3 | 205.66 Thousand USD | -3.3% |
| 2019 Q2 | 212.67 Thousand USD | 38.59% |
| 2019 Q1 | 153.45 Thousand USD | 12.32% |
| 2019 Q4 | 208.82 Thousand USD | 1.54% |
| 2019 FY | 208.82 Thousand USD | 52.84% |
| 2018 Q4 | 136.62 Thousand USD | -16.25% |
| 2018 FY | 136.62 Thousand USD | 212.42% |
| 2018 Q1 | 89.24 Thousand USD | 104.08% |
| 2018 Q2 | 128.56 Thousand USD | 44.06% |
| 2018 Q3 | 163.13 Thousand USD | 26.88% |
| 2017 Q3 | 72.58 Thousand USD | -33.95% |
| 2017 FY | 43.73 Thousand USD | -58.35% |
| 2017 Q4 | 43.73 Thousand USD | -39.75% |
| 2017 Q2 | 109.87 Thousand USD | 73.55% |
| 2017 Q1 | 63.31 Thousand USD | -39.7% |
| 2016 Q1 | 132.49 Thousand USD | -6.68% |
| 2016 Q2 | 134.86 Thousand USD | 1.78% |
| 2016 Q3 | 127.89 Thousand USD | -5.16% |
| 2016 Q4 | 105 Thousand USD | -17.9% |
| 2016 FY | 105 Thousand USD | -26.05% |
| 2015 Q2 | 137.17 Thousand USD | 2.39% |
| 2015 Q1 | 133.98 Thousand USD | -12.38% |
| 2015 FY | 141.99 Thousand USD | -7.14% |
| 2015 Q3 | 114.89 Thousand USD | -16.24% |
| 2015 Q4 | 141.99 Thousand USD | 23.58% |
| 2014 Q2 | 179.12 Thousand USD | 30.57% |
| 2014 Q3 | 194.82 Thousand USD | 8.77% |
| 2014 Q1 | 137.19 Thousand USD | 54.86% |
| 2014 Q4 | 152.9 Thousand USD | -21.52% |
| 2014 FY | 152.9 Thousand USD | 72.6% |
| 2013 FY | 88.59 Thousand USD | 42.97% |
| 2013 Q4 | 88.59 Thousand USD | -2.03% |
| 2013 Q2 | 45.52 Thousand USD | -66.5% |
| 2013 Q1 | 135.9 Thousand USD | 119.32% |
| 2013 Q3 | 90.42 Thousand USD | 98.62% |
| 2012 FY | 61.96 Thousand USD | -14.94% |
| 2012 Q4 | 61.96 Thousand USD | 30.24% |
| 2012 Q3 | 47.57 Thousand USD | 30.18% |
| 2012 Q2 | 36.54 Thousand USD | -60.22% |
| 2012 Q1 | 91.88 Thousand USD | 26.13% |
| 2011 FY | 72.85 Thousand USD | 1.95% |
| 2011 Q4 | 72.85 Thousand USD | 49.18% |
| 2011 Q3 | 48.83 Thousand USD | -61.49% |
| 2011 Q2 | 126.82 Thousand USD | 45.08% |
| 2011 Q1 | 87.41 Thousand USD | 22.33% |
| 2010 Q3 | 113.07 Thousand USD | -44.24% |
| 2010 Q1 | 128.85 Thousand USD | 24.13% |
| 2010 Q2 | 202.78 Thousand USD | 57.37% |
| 2010 Q4 | 71.45 Thousand USD | -36.8% |
| 2010 FY | 71.45 Thousand USD | -31.16% |
| 2009 Q2 | 88.48 Thousand USD | 8.95% |
| 2009 Q3 | 57.19 Thousand USD | -35.36% |
| 2009 Q4 | 103.8 Thousand USD | 81.49% |
| 2009 FY | 103.8 Thousand USD | 51.41% |
| 2009 Q1 | 81.21 Thousand USD | 18.46% |
| 2008 Q3 | 86.41 Thousand USD | -2.82% |
| 2008 Q4 | 68.55 Thousand USD | -20.67% |
| 2008 Q1 | 96.11 Thousand USD | 45.41% |
| 2008 Q2 | 88.92 Thousand USD | -7.48% |
| 2008 FY | 68.55 Thousand USD | 3.71% |
| 2007 FY | 66.1 Thousand USD | 33.01% |
| 2007 Q4 | 66.1 Thousand USD | 63.21% |
| 2007 Q3 | 40.5 Thousand USD | -29.86% |
| 2007 Q2 | 57.74 Thousand USD | -19.96% |
| 2007 Q1 | 72.14 Thousand USD | 45.16% |
| 2006 Q1 | 85.73 Thousand USD | -1.05% |
| 2006 FY | 49.69 Thousand USD | -42.64% |
| 2006 Q4 | 49.69 Thousand USD | -0.61% |
| 2006 Q3 | 50 Thousand USD | -23.26% |
| 2006 Q2 | 65.15 Thousand USD | -24.0% |
| 2005 Q4 | 86.64 Thousand USD | -15.76% |
| 2005 Q2 | 132.37 Thousand USD | 43.33% |
| 2005 Q1 | 92.35 Thousand USD | -13.48% |
| 2005 Q3 | 102.85 Thousand USD | -22.3% |
| 2005 FY | 86.64 Thousand USD | -18.82% |
| 2004 Q3 | 110.11 Thousand USD | 31.58% |
| 2004 Q2 | 83.68 Thousand USD | -23.31% |
| 2004 Q4 | 106.73 Thousand USD | -3.06% |
| 2004 FY | 106.73 Thousand USD | 51.5% |
| 2004 Q1 | 109.12 Thousand USD | 54.89% |
| 2003 FY | 70.45 Thousand USD | 21.81% |
| 2003 Q3 | 87.11 Thousand USD | 62.8% |
| 2003 Q4 | 70.45 Thousand USD | -19.12% |
| 2003 Q2 | 53.5 Thousand USD | -27.9% |
| 2003 Q1 | 74.21 Thousand USD | 28.32% |
| 2002 FY | 57.83 Thousand USD | -32.01% |
| 2002 Q3 | 27.53 Thousand USD | -35.67% |
| 2002 Q1 | 111.51 Thousand USD | 31.1% |
| 2002 Q2 | 42.79 Thousand USD | -61.63% |
| 2002 Q4 | 57.83 Thousand USD | 110.07% |
| 2001 Q2 | 104.68 Thousand USD | -12.4% |
| 2001 Q4 | 85.06 Thousand USD | -32.92% |
| 2001 FY | 85.06 Thousand USD | -59.3% |
| 2001 Q1 | 119.5 Thousand USD | -42.83% |
| 2001 Q3 | 126.81 Thousand USD | 21.14% |
| 2000 FY | 209.02 Thousand USD | -38.42% |
| 2000 Q4 | 209.02 Thousand USD | 0.0% |
| 1999 FY | 339.4 Thousand USD | -59.37% |
| 1998 FY | 835.38 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Arch Therapeutics, Inc. | 9.46 Million USD | 99.71% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.962% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 96.608% |
| Rebus Holdings, Inc. | 5.24 Million USD | 99.477% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 99.954% |
| Qrons Inc. | 1.48 Million USD | 98.157% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | 97.763% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.963% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | 38.623% |
| Skye Bioscience, Inc. | 14.07 Million USD | 99.805% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 99.949% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 99.714% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | 93.493% |
| SQZ Biotechnologies Company | 50.03 Million USD | 99.945% |
| Intellipharmaceutics International Inc. | 12 Million USD | 99.772% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 99.288% |
| Mesoblast Limited | 188.44 Million USD | 99.985% |
| Marizyme, Inc. | 26.67 Million USD | 99.897% |
| Genus plc | 485 Million USD | 99.994% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 99.53% |
| Pharming Group N.V. | 244.07 Million USD | 99.989% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 98.635% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 98.91% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 99.278% |
| ContraFect Corporation | 32.53 Million USD | 99.916% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 98.615% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 99.283% |
| IMV Inc. | 37.93 Million USD | 99.928% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 99.767% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1595.834% |
| ONE Bio Corp. | 27.49 Million USD | 99.9% |
| Accustem Sciences Inc. | 1.07 Million USD | 97.458% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.965% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 98.703% |
| Q BioMed Inc. | 8.13 Million USD | 99.663% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.967% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 99.467% |
| Biomind Labs Inc. | 1.49 Million USD | 98.169% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.977% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 99.697% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 99.851% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 98.087% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | 80.694% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | 86.36% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 99.523% |
| GB Sciences, Inc. | 5.41 Million USD | 99.494% |
| Alpha Cognition Inc. | 7.16 Million USD | 99.617% |
| HST Global, Inc. | 593.59 Thousand USD | 95.378% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 97.821% |
| Halberd Corporation | 728.71 Thousand USD | 96.235% |
| Enzolytics Inc. | 365.26 Million USD | 99.992% |
| Agentix Corp. | 2.51 Million USD | 98.907% |
| Resverlogix Corp. | 67.39 Million USD | 99.959% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 96.729% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.994% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 98.399% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 99.889% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 99.77% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 99.252% |
| AVAX Technologies, Inc. | 3.99 Million USD | 99.313% |
| Zenith Capital Corp. | 27.56 Thousand USD | 0.493% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.998% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | 88.505% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 99.265% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 95.971% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 98.988% |
| Kadimastem Ltd | 3.5 Million USD | 99.217% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | 59.012% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 99.945% |
| BioStem Technologies, Inc. | 15.9 Million USD | 99.828% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | 94.097% |
| LadRx Corporation | 2.2 Million USD | 98.753% |
| Cell Source, Inc. | 15.8 Million USD | 99.826% |
| Regen BioPharma, Inc. | 5.45 Million USD | 99.497% |
| Regen BioPharma, Inc. | 5.45 Million USD | 99.497% |
| NovAccess Global Inc. | 7.86 Million USD | 99.651% |
| Affymax, Inc. | 8.87 Million USD | 99.691% |
| Itoco Inc. | 1.65 Million USD | 98.341% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 98.663% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 99.546% |
| Mobile Lads Corp. | 1.31 Million USD | 97.911% |
| CytoDyn Inc. | 127.89 Million USD | 99.979% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | 34.369% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 98.249% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 99.752% |
| SYBLEU INC | 681.41 Thousand USD | 95.974% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 99.55% |
| International Stem Cell Corporation | 5.27 Million USD | 99.48% |
| Bioxytran, Inc. | 3.24 Million USD | 99.156% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 95.616% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 99.406% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 99.933% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 99.877% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 98.646% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 99.499% |
| Neutra Corp. | 973.52 Thousand USD | 97.182% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 99.905% |
| PureTech Health plc | 125.58 Million USD | 99.978% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 99.27% |
| IXICO plc | 1.9 Million USD | 98.556% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 99.866% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.973% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Cellectis S.A. | 249.36 Million USD | 99.989% |